替戈拉生联合伊托必利治疗反流性食管炎患者的效果及安全性  

Efficacy and safety of tegoprazan combined with itopride in treatment of reflux esophagitis

作　　者：赵文涛 孙涵 焦小红 Zhao Wen-tao;Sun Han;Jiao Xiao-hong(Department of Gastroenterology,417 Hospital of Nuclear Industry,Xi’an 710600,China)

机构地区：[1]核工业四一七医院消化内科,西安710600

出　　处：《中国药物应用与监测》2025年第1期34-37,共4页Chinese Journal of Drug Application and Monitoring

摘　　要：目的观察替戈拉生联合伊托必利治疗反流性食管炎(RE)的效果及安全性。方法选取核工业四一七医院2022年5月至2024年5月收治的RE患者94例为此次试验对象,按照随机数字表法将患者分成两组,对照组(n=47)口服盐酸伊托必利片、雷贝拉唑钠肠溶片,观察组(n=47)口服伊托必利、替戈拉生,两组均连续治疗8周。比较两组临床疗效,治疗前后胃肠激素浓度、表皮生长因子受体(EGFR)阳性表达情况以及不良反应发生情况。结果观察组临床总有效率97.87%(46/47)相较于对照组的82.98%(39/47)更高,EGFR阳性表达率82.98%(39/47)较对照组61.70%(29/47)更高(χ^(2)=6.021、5.317,均P<0.05)。治疗后,观察组血清胃泌素-17(G-17)、胃蛋白酶原Ⅱ(PGⅡ)水平[分别为(106.26±8.33)pg·mL^(-1)、(15.32±1.27)μg·L^(-1)]均低于对照组[分别为(115.58±9.17)pg·mL^(-1)、(21.71±2.35)μg·L^(-1)](t=5.528、17.579,均P<0.05),观察组胃蛋白酶原Ⅰ(PGⅠ)[(131.68±10.71)μg·L^(-1)]高于对照组[(122.59±9.46)μg·L^(-1)](t=4.675,P<0.05)。观察组不良反应总发生率为10.64%(5/47),与对照组的14.89%(7/47)对比差异无统计学意义(χ^(2)=0.382,P>0.05)。结论替戈拉生联合伊托必利治疗RE患者临床疗效显著,可改善患者胃肠激素水平,且安全性高。Objective To investigate the efficacy and safety of tegoprazan combined with itopride in the treatment of reflux esophagitis(RE).Methods A total of 94 RE patients admitted to 417 Hospital of Nuclear Industry from May 2022 to May 2024 were selected and divided into 2 groups using the random table method.The patients in the control group(n=47)were given oral itopride hydrochloride tablets and rabeprazole sodium enteric-coated tablets while those in the observation group(n=47)were given oral itopride and tegoprazan.All the patients in both groups were treated continuously for 8 weeks.The clinical efficacy,positive expression of epidermal growth factor receptor(EGFR)and adverse reactions were compared between the two groups.Results The total effective rate and EGFR positive expression rate were significantly higher in the observation group than in the control(97.87%(46/47)vs 82.98%(39/47),82.98%(39/47)vs 61.70%(29/47))(χ^(2)=6.021,5.317,both P<0.05).After treatment,the levels of serum gastrin-17(G-17)and pepsinogenⅡ(PGⅡ)in the observation group were(106.26±8.33)pg·mL^(-1) and(15.32±1.27)μg·L^(-1),which were lower than those of(115.58±9.17)pg·mL^(-1) and(21.71±2.35)μg·L^(-1) in the control(t=5.528,17.579,both P<0.05).PepsinogenⅠ(PG-Ⅰ)was(131.68±10.71)μg·L^(-1) in the observation group,which was higher than that of(122.59±9.46)μg·L^(-1) in the control(t=4.675,P<0.05).The total incidence of adverse reactions showed no significant difference between the two groups(10.64%,5/47 vs 14.89%,7/47)(χ^(2)=0.382,P>0.05).Conclusion Tegoprazan combined with itopride has significant efficacy in the treatment of RE patients since it can improve the level of gastrointestinal hormones.Meanwhile,it is of high safety.

关 键 词：替戈拉生 伊托必利 反流性食管炎 胃肠激素 表皮生长因子受体 安全性 

分 类 号：R571[医药卫生—消化系统]